此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

用于预防移植后糖尿病的半卢比特 (SPOT-DM)

2026年11月4日 更新者:Sunita Singh, MD, MSc, FRCPC、University Health Network, Toronto

The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of semaglutide therapy in 37 KTR at risk of post-transplant diabetes mellitus (PTDM).

研究概览

详细说明

A kidney transplant is the best treatment for people living with kidney failure as it allows people to live longer with a better quality of life. However, one in four kidney transplant recipients will develop diabetes after transplant. This is largely due to the medications that must be used to prevent rejection of the transplant. Kidney transplant recipients who get diabetes after transplant are up to three times more likely to have heart disease and die prematurely. To date, there are no treatments to prevent the development of diabetes after kidney transplant. Semaglutide is a drug that is commonly used to treat diabetes and obesity. The investigators believe that semaglutide is a safe and effective drug which can prevent the development of diabetes in kidney transplant recipients. Therefore, the investigators are conducting a study where kidney transplant recipients who are at increased risk of developing diabetes after transplant will receive semaglutide for 24 weeks after their transplant. The study will determine whether semaglutide is effective in decreasing blood sugar levels and the rate of diabetes. The investigators will also study other important markers of health including body weight and cholesterol levels as well as liver, kidney and heart function. Diabetes after transplant is a common problem, and preventing it is extremely important to allowing kidney transplant recipients to live longer and better lives. The results of this study will allow the investigators to determine if semaglutide is a safe and effective option for the prevention of diabetes in kidney transplant recipients.

研究类型

介入性

注册 (估计的)

37

阶段

  • 阶段2
  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Cheng Xu
  • 电话号码:8508 416-340-4800
  • 邮箱:cheng.xu@uhn.ca

学习地点

    • British Columbia
      • Vancouver、British Columbia、加拿大、V6Z 1Y6
        • St. Paul's Hospital
        • 接触:
    • Ontario
      • Toronto、Ontario、加拿大、M5G 2N2
        • Toronto General Hospital
        • 接触:
        • 首席研究员:
          • Sunita Singh, MD MSc FRCPC

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Signed and dated written informed consent.

  2. Adult (≥18 years) recipients of a living or deceased donor kidney transplant

  3. Between 4- and 12-weeks post kidney transplant

  4. Stable kidney function defined as an eGFR > 30 ml/min/1.73m2 (CKD-EPI)

  5. At risk for PTDM at the time of transplant based on the following criteria:

    1. BMI ≥ 25 kg/m2, or
    2. Fasting plasma glucose 6.1-6.9 mmol/L (impaired fasting glucose), or
    3. 2hr OGTT plasma glucose 7.8-11.0 (impaired glucose tolerance), or
    4. HbA1C 5.5-6.4% (at risk for DM or prediabetes).

Exclusion Criteria:

  1. Established diagnosis of type 1 or type 2 DM as per Diabetes Canada (including the need for glucose-lowering therapy for hyperglycemia at the time of screening)
  2. Kidney-Pancreas transplant recipient
  3. Acute coronary syndrome, transient ischemic attack or stroke within 30 days prior to screening
  4. History of pancreatitis
  5. Personal or family history of medullary thyroid cancer or MEN2B
  6. Women who are pregnant, nursing or plan on becoming pregnant whilst in the trial
  7. Use of GLP1RA in the 30 days prior to screening
  8. Contraindication to MRI (applicable only to those undergoing the optional MRI assessments)
  9. With known or suspected hypersensitivity to semaglutide or related products
  10. Patient not able to understand and comply with study requirements, based on Investigator's judgment.
  11. Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcom
  12. History of glucose-galactose malabsorption syndrome

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Semaglutide

Patients will be up-titrated as tolerated starting at 0.25 mg subcutaneous semaglutide once weekly for 4 weeks, followed by 0.5 mg, 1.0 mg, and 1.7 mg semaglutide for 4 weeks each, and then 2.4 mg subcutaneous semaglutide once weekly for 8 weeks. Semaglutide can be down-titrated by the investigator to lower doses or up-titrated at slower rates if not tolerated by the participant.

Subcutaneous semaglutide 0.25mg for 4 weeks.

Subcutaneous semaglutide 0.5mg for 4 weeks.

Subcutaneous semaglutide 1.0 mg for 4 weeks.

Subcutaneous semaglutide 1.7 mg for 4 weeks

Subcutaneous semaglutide 2.4 mg for 8 weeks

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
2-hour OGTT
大体时间:24 weeks

The primary outcome of this study is the change in plasma glucose at 120 minutes following a 75g oral glucose challenge (2-hour OGTT) at 24 weeks. The 2-hour OGTT was selected as the primarily outcome in this study for the following reasons: 1) In selecting a surrogate outcome for PTDM in KTR, there are limitations to HbA1c and fasting glucose in this population; 2) The 2-hour OGTT is the recommended test for the diagnosis of PTDM in KTR and 3) The use of OGTT has been used in other PTDM prevention studies.

24 weeks

次要结果测量

结果测量
措施说明
大体时间
收缩压
大体时间:24周
24周
体重变化
大体时间:24周
24周
腰围变化
大体时间:24周
24周
HbA1c 的变化
大体时间:24周
24周
更换空腹血糖
大体时间:24周
24周
血清胰岛素的变化
大体时间:24周
24周
更改禁食脂质曲线
大体时间:24周
24周
舒张压
大体时间:24周
24周
平均动脉压
大体时间:24周
24周
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
大体时间:24 weeks

: The side effects of GLP-1RA have been well described and will be assessed at each study visit. Adverse events include AKI, hypoglycemia, volume depletion, GI intolerance, amputations, pancreatitis, hepatobiliary complications and injection site or allergic reactions, infectious complications (any source), and malignancy. Episodes of biopsy-proven acute rejection (as defined by the Banff criteria), death-censored graft failure (defined as the need for initiation of chronic dialysis or re-transplantation) or death with graft function (defined as death with a functioning allograft) will also be collected. Kidney transplantation assures complete denervation of the transplanted kidney and the renal vasoconstrictive response in the setting of intravascular volume depletion is diminished in KTR. Therefore, frequent monitoring for adverse events has been integrated in our study design, occurring on 10 separate occasions, to capture these adverse events should they occur.

24 weeks
Estimated GFR
大体时间:24 weeks

Calculated by CKD-EPI 2021 equation

24 weeks
GFR
大体时间:24 weeks

Measured using 24-urine collection for creatinine, standardized per 1.73m2 body surface area. And estimated using CKD-EPI 2021 equation.

24 weeks
Albuminuria
大体时间:24 weeks

measuring urine albumin excretion from a 24-hour urine collection

24 weeks
Natriuresis
大体时间:24 weeks

Assessed with a 24-hour urine collection for sodium excretion

24 weeks
Percentage of body fat
大体时间:24 weeks

Bioimpedance analysis

24 weeks
Change in liver enzymes
大体时间:24 weeks

ALT and AST

24 weeks
Change in fibrosis level
大体时间:24 weeks

Transient elastography

24 weeks
Change in steatosis level
大体时间:24 weeks

Transient elastography

24 weeks
Percentage of extracellular fluid
大体时间:24 weeks

Bioimpedance analysis

24 weeks

其他结果措施

结果测量
措施说明
大体时间
Change in kidney oxygenation (R2*)
大体时间:24 weeks

Assessed via multiparametric kidney MRI in an optional cohort.

24 weeks
Change in kidney fibrosis (ADC)
大体时间:24 weeks

Assessed via multiparametric kidney MRI in an optional cohort.

24 weeks
Change in kidney perfusion
大体时间:24 weeks

Assessed via multiparametric kidney MRI in an optional cohort.

24 weeks
Change in kidney volume
大体时间:24 weeks

Assessed via multiparametric kidney MRI in an optional cohort.

24 weeks
Change in kidney inflammation (T1)
大体时间:24 weeks

Assessed via multiparametric kidney MRI in an optional cohort.

24 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Sunita Singh, MD MSc FRCPC、University Health Network, Toronto General Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月5日

初级完成 (估计的)

2029年6月30日

研究完成 (估计的)

2029年12月30日

研究注册日期

首次提交

2025年3月17日

首先提交符合 QC 标准的

2025年4月2日

首次发布 (实际的)

2025年4月6日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • 25-5093

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅